Managing vasomotor symptoms effectively without hormones

References

• Davis SR, Lambrinoudaki I, Lumsden M, et al. Menopause. Nat Rev Dis Primers 2015;1:15004
   PubMed Web of Science ®Google Scholar
• Carpenter JS, Woods NF, Otte JL, et al. MsFLASH participants’ priorities for alleviating menopausal symptoms. Climacteric 2015;18:859–66
   PubMed Web of Science ®Google Scholar
• Prague JK, Dhillo WS. Treating hot flushes with a neurokinin 3 receptor antagonist. Oncotarget 2017;8:106153–4
   PubMedGoogle Scholar
• Prague JK, Dhillo WS. Neurokinin 3 receptor antagonism – the magic bullet for hot flushes? Climacteric 2017;20:505–9
   PubMed Web of Science ®Google Scholar
• Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175:531–9
   PubMed Web of Science ®Google Scholar
• Marino JL, Saunders CM, Emery L, Green H, Doherty DA, Hickey M. Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history. Menopause 2014;21:267–74
   PubMed Web of Science ®Google Scholar
• Iliodromiti S, Wang W, Lumsden MA, et al. Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review. BJOG 2020;127:320–33
   PubMed Web of Science ®Google Scholar
• Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017;1:CD004143
   PubMed Web of Science ®Google Scholar
• Hickey M, Szabo RA, Hunter MS. Non-hormonal treatments for menopausal symptoms. BMJ 2017;359:j5101
   PubMedGoogle Scholar
• Kim N, Gross C, Curtis J, et al. The impact of clinical trials on the use of hormone replacement therapy. a population-based study. J Gen Intern Med 2005;20:1026–31
   PubMed Web of Science ®Google Scholar
• de Jong-van den Berg LT, Faber A, van den Berg PB. HRT use in 2001 and 2004 in The Netherlands-a world of difference. Maturitas 2006;54:193–7
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA 2017;318:927–38
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394:1159–68
   PubMed Web of Science ®Google Scholar
• Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause 2012;19:749–59
   PubMed Web of Science ®Google Scholar
• Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause 2013;20:291–8
   PubMed Web of Science ®Google Scholar
• Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol 2008;26:5022–6
   PubMed Web of Science ®Google Scholar
• Franco OH, Chowdhury R, Troup J, et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA 2016;315:2554–63
   PubMed Web of Science ®Google Scholar
• Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998;16:495–500
   PubMed Web of Science ®Google Scholar
• Gold EB, Crawford SL, Shelton JF, et al. Longitudinal analysis of changes in weight and waist circumference in relation to incident vasomotor symptoms: the Study of Women’s Health Across the Nation (SWAN). Menopause 2017;24:9–26
   PubMed Web of Science ®Google Scholar
• Thurston RC, Sowers MR, Sternfeld B, et al. Gains in body fat and vasomotor symptom reporting over the menopausal transition: the Study of Women’s Health Across the Nation. Am J Epidemiol 2009;170:766–74
   PubMed Web of Science ®Google Scholar
• Thurston RC, Ewing LJ, Low CA, Christie AJ, Levine MD. Behavioral weight loss for the management of menopausal hot flashes: a pilot study. Menopause 2015;22:59–65
   PubMed Web of Science ®Google Scholar
• Lund KS, Siersma V, Brodersen J, Waldorff FB. Efficacy of a standardised acupuncture approach for women with bothersome menopausal symptoms: a pragmatic randomised study in primary care (the ACOM study). BMJ Open 2019;9:e023637
   PubMed Web of Science ®Google Scholar
• Dodin S, Blanchet C, Marc I, et al. Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev 2013;(7):CD007410
   Google Scholar
• Kauffman RP. Telephone-based CBT reduced insomnia severity more than menopause education in menopausal women. Ann Intern Med 2016;165:JC30
   PubMed Web of Science ®Google Scholar
• Guthrie KA, Larson JC, Ensrud KE, et al. Effects of pharmacologic and nonpharmacologic interventions on insomnia symptoms and self-reported sleep quality in women with hot flashes: a pooled analysis of individual participant data from four MsFLASH trials. Sleep 2018;41: zsx190
   PubMed Web of Science ®Google Scholar
• Green SM, Donegan E, Frey BN, et al. Cognitive behavior therapy for menopausal symptoms (CBT-Meno): a randomized controlled trial. Menopause 2019;26:972–80
   PubMed Web of Science ®Google Scholar
• Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol 2012;13:309–18
   PubMed Web of Science ®Google Scholar
• Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015;22:1155–72
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
   PubMed Web of Science ®Google Scholar
• Saensak S, Vutyavanich T, Somboonporn W, Srisurapanont M. Relaxation for perimenopausal and postmenopausal symptoms. Cochrane Database Syst Rev 2014;(7):CD008582
   Google Scholar
• Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2014;(11):CD006108
   Google Scholar
• Daley AJ, Thomas A, Roalfe AK, et al. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial. BJOG 2015;122:565–75
   PubMed Web of Science ®Google Scholar
• Royal College of Obstetricians and Gynaecologists. Treatment for symptoms of the menopause. 2018. Available from: https://www.rcog.org.uk/globalassets/documents/patients/patient-information-leaflets/gynaecology/pi-treatment-symptoms-menopause.pdf. [last accessed May 11, 2020]
   Google Scholar
• Cramer H, Peng W, Lauche R. Yoga for menopausal symptoms–a systematic review and meta-analysis. Maturitas 2018;109:13–25
   PubMed Web of Science ®Google Scholar
• Goughnour SL, Thurston RC, Althouse AD, et al. Assessment of hot flushes and vaginal dryness among obese women undergoing bariatric surgery. Climacteric 2016;19:71–6
   PubMed Web of Science ®Google Scholar
• Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: an endocrine society scientific statement. Endocr Rev 2018;39:79–132
   PubMed Web of Science ®Google Scholar
• Carpenter JS, Burns DS, Wu J, et al. Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial. J Gen Intern Med 2013;28:193–200
   PubMed Web of Science ®Google Scholar
• Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev 2013;(12):CD001395
   Google Scholar
• Mintziori G, Lambrinoudaki I, Goulis DG, et al. EMAS position statement: non-hormonal management of menopausal vasomotor symptoms. Maturitas 2015;81:410–13
   PubMed Web of Science ®Google Scholar
• Zhu X, Liew Y, Liu ZL. Chinese herbal medicine for menopausal symptoms. Cochrane Database Syst Rev 2016;3:CD009023
   PubMedGoogle Scholar
• Mahady GB, Parrot J, Lee C, Yun GS, Dan A. Botanical dietary supplement use in peri- and postmenopausal women. Menopause 2003;10:65–72
   PubMed Web of Science ®Google Scholar
• National Institute for Health Care and Excellence [ng23]. Menopause: diagnosis and management. November 2015. Available from: https://www.nice.org.uk/guidance/ng23 [last accessed May 11, 2020]
   Google Scholar
• Biglia N, Sgandurra P, Peano E, et al. Non-hormonal treatment of hot flushes in breast cancer survivors: Gabapentin vs. vitamin E. Climacteric 2009;12:310–18
   PubMed Web of Science ®Google Scholar
• Walega DR, Rubin LH, Banuvar S, Shulman LP, Maki PM. Effects of stellate ganglion block on vasomotor symptoms: findings from a randomized controlled clinical trial in postmenopausal women. Menopause 2014;21:807–14
   PubMed Web of Science ®Google Scholar
• Rahimzadeh P, Imani F, Nafissi N, Ebrahimi B, Faiz S. Comparison of the effects of stellate ganglion block and paroxetine on hot flashes and sleep disturbance in breast cancer survivors. Cancer Manag Res 2018;10:4831–7
   PubMed Web of Science ®Google Scholar
• Chiu HY, Pan CH, Shyu YK, Han BC, Tsai PS. Effects of acupuncture on menopause-related symptoms and quality of life in women in natural menopause: a meta-analysis of randomized controlled trials. Menopause 2015;22:234–44
   PubMed Web of Science ®Google Scholar
• Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267–74
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Freeman EW, Larson J, et al. Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. Maturitas 2012;73:361–8
   PubMed Web of Science ®Google Scholar
• Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013;20:1027–35
   PubMed Web of Science ®Google Scholar
• Pae CU, Park MH, Marks DM, Han C, Patkar AA, Masand PS. Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Curr Opin Investig Drugs 2009;10:75–90
   PubMedGoogle Scholar
• Simon JA, Chandler J, Gottesdiener K, et al. Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetine. Menopause 2014;21:938–44
   PubMed Web of Science ®Google Scholar
• Speroff L, Gass M, Constantine G, Olivier S, Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77–87
   PubMed Web of Science ®Google Scholar
• Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014;174:1058–66
   PubMed Web of Science ®Google Scholar
• Caan B, LaCroix AZ, Joffe H, et al. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial. Menopause 2015;22:607–15
   PubMed Web of Science ®Google Scholar
• Cobin RH, Goodman NF, American association of clinical endocrinologists and American college of endocrinology position statement on MENOPAUSE-2017 UPDATE. Endocr Pract 2017;23:869–80
   PubMed Web of Science ®Google Scholar
• Birkhaeuser M, Bitzer J, Braat S, Ramos Y. Esmirtazapine treatment of postmenopausal vasomotor symptoms: two randomized controlled trials. Climacteric 2019;22:312–22
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017;6:CD007938
   PubMedGoogle Scholar
• Pinkerton JV, Kagan R, Portman D, et al. Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. Menopause 2014;21:567–73
   PubMed Web of Science ®Google Scholar
• Saadati N, Mohammadjafari R, Natanj S, Abedi P. The effect of gabapentin on intensity and duration of hot flashes in postmenopausal women: a randomized controlled trial. Glob J Health Sci 2013;5:126–30
   PubMedGoogle Scholar
• Shan D, Zou L, Liu X, Shen Y, Cai Y, Zhang J. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. Am J Obstet Gynecol 2019;222:564–579.e12
   PubMed Web of Science ®Google Scholar
• Rahmanian M, Mohseni A, Ghorbani R. A crossover study comparing gabapentin and fluoxetine for the treatment of vasomotor symptoms among postmenopausal women. Int J Gynaecol Obstet 2015;131:87–90
   PubMed Web of Science ®Google Scholar
• Australasian Menopause Society. Non-hormonal treatments for menopausal symptoms. 2017. Available from: https://www.menopause.org.au/images/stories/infosheets/docs/AMS_Nonhormonal_Treatments_for_Menopausal_Symptoms.pdf [last accessed May 11, 2020]
   Google Scholar
• ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 2014;123:202–16
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Qin R, Balcueva EP, et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 2010;28:641–7
   PubMed Web of Science ®Google Scholar
• Boekhout AH, Vincent AD, Dalesio OB, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2011;29:3862–8
   PubMed Web of Science ®Google Scholar
• Edington RF, Chagnon JP, Steinberg WM. Clonidine (Dixarit) for menopausal flushing. Can Med Assoc J 1980;123:23–6
   PubMed Web of Science ®Google Scholar
• Bolli P, Simpson FO. Clonidine in menopausal flushing: a double-blind trial. N Z Med J 1975;82:196–7
   PubMed Web of Science ®Google Scholar
• Wren BG, Brown LB. A double-blind trial with clonidine and a placebo to treat hot flushes. Med J Aust 1986;144:369–70
   PubMed Web of Science ®Google Scholar
• Simon JA, Gaines T, LaGuardia KD. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. Menopause 2016;23:1214–21
   PubMed Web of Science ®Google Scholar
• Leon-Ferre RA, Novotny PJ, Wolfe EG, et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectr 2019;4:pkz088
   PubMed Web of Science ®Google Scholar
• Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab 2019;104:5893–905
   PubMed Web of Science ®Google Scholar
• Astellas. Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms 2019. Available from: www.astellas.com/en/news/14866 [last accessed 23 Feb 2020]
   Google Scholar
• Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;(4):CD002978
   PubMedGoogle Scholar
• Pan Y, Meister R, Löwe B, et al. Non-concealed placebo treatment for menopausal hot flushes: study protocol of a randomized-controlled trial. Trials 2019;20:508
   PubMedGoogle Scholar